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Abstract
Aim The aim of the present review was to characterize the
potential of different biomaterials as carriers for bone
growth factors.
Introduction Beyond mechanical and structural character-
istics, one of the features that account for a potential carrier
is the possibility to couple growth factor molecules to it. As
simple adsorption of the growth factor to the carrier surface
by soak loading produces a burst release of growth factors
with rapid decrease of biological activity, the ability to
accomplish controlled release of functional growth factor
molecules is one of the crucial characteristics for an
appropriate carrier material.
Conclusion The variety of carrier materials requires differ-
ent strategies to either couple growth factors to the material
surface or to incorporate them into the carrier matrix. The
present review outlines current technical approaches and
discusses future trends in the use of carrier materials for
bone growth factors.
Keywords Growth factors . Carriers . Biomaterials .
Osteoinduction . Regenerative medicine
Introduction
Applications of biological signals in regenerative medicine
require carrier systems for targeted delivery with respect to
both location and dosage. Bone growth factors are expected
to enhance or to accomplish bone formation in defects that
would otherwise require autogenous bone tissue transfer for
repair. In order to fulfill these expectations, the ideal carrier
system would provide mechanical strength for bridging of
bone defects and resistance against soft tissue pressure on
the one hand as well as interconnecting porosity and
degradability for unrestricted bone ingrowth and final
replacement by regenerated bone on the other. Many
biomaterials can act as passive scaffolds in this way;
however, in order to qualify for a growth factor carrier,
they have to be loadable with biologically active mole-
cules and allow for retarded delivery and controlled
presentation. The carrier systems for osteogenic growth
factors that are in clinical use or undergo current clinical
testing are loaded either by soaking the carrier into the
growth factor solution for immediate application or they
are submitted to soaking and lyophylization for storage
and later use. Delivery from these carriers occurs through
a burst release with loss of up to 80% of activity within
the first 48 h after implantation [39]. Although the dosage
requirements for osteogenic growth factors have not yet
been clearly defined, there is wide agreement that con-
trolled release of growth factors is more likely to
approximate natural delivery characteristics than the burst
release provided by the carriers currently in use.
Loading of a potential carrier with growth factors can be
accomplished either through various ways of binding the
growth factor molecules to the material surface or by
incorporating them into the biomaterial itself. The strategies
for biofunctionalization of carriers with growth factors,
thus, depend very much on the characteristics of the carrier
material with respect to degradability. For permanent
materials, loading of the carrier surface with growth factors
would be an appropriate approach, whereas for degradable
carriers, incorporation of these molecules into the carrier
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matrix for gradual release during degradation would be
desirable. Sophisticated technology to anchor biologically
active molecules to the surface of degradable materials
would not be useful as surface erosion during early stages
of degradation would rapidly extinguish the biological
activity and leave a passive scaffold behind.
All biomaterials that are potential candidates as growth
factor carriers have their individual limitations with respect
to binding or incorporation of growth factors that are based
on their chemistry and have to be specifically addressed by
individually adapted technology. With respect to material
chemistry, a gross distinction between inorganic and
organic carriers may be useful for a systematic approach.
While most of the former ones fall into the realm of dental
implants and bone replacement materials, the latter ones
provide a wide variety of new polymeric materials, most of
them being still under development.
Inorganic carriers
Inorganic carriers can be grouped into metals and
mineralized carriers, the latter ones being split up into
scaffolds of natural and synthetic origin. The conditions
and temperatures used during fabrication of inorganic
carriers commonly preclude the inclusion of bioactive
molecules into the material itself. Only nanocrystalline
calcium phosphate cements that are prepared at room
temperature and cure at body temperature may be suitable
for the integration of growth factors into the biomaterial
itself. However, the approaches that have been evaluated
in preclinical experimental settings have not been suc-
cessful yet [18]. Thus, inorganic carriers can be considered
as being functionalized merely by coupling biologically
active molecules to the material surface.
The least complex way of binding growth factor
molecules to the surface of an inorganic biomaterial is
adsorption during immersion of the material into the
solution of the respective growth factor. Adsorptive binding
can occur through physisorption or chemisorption [28].
Physisorption is based on the fact the most inorganic
biomaterial surfaces are negatively charged and that
positively charged proteins can bind to these negative
surface charges. Release of physisorbed molecules is
influenced by the chemical nature of the material and the
actual chemical status of its surfaces. Titanium surfaces that
have been loaded with bone morphogenic proteins (BMPs)
by physisorption have lost 99% to 96% of their bioactivity
during the first hours of release depending on their
microstructure [11]. In contrast, diamond coating of
titanium surfaces could achieve a much stronger binding
of BMP molecules to the surface [36] with a considerably
retarded release in vitro and increased bone formation in
vivo depending on its oxidative status [20]. Physisorption
has also been used to bind structural proteins such as
collagen to titanium surfaces. Collagen provides numerous
bindings sites for integrin receptors on the surface of
osteoblasts and precursor cells and can act as well as a
reservoir for growth factors in conjunction with other bone
matrix components such as glycosaminoglycans. In this
way, coadsorption of collagen and chondroitin sulfate to
titanium surfaces has been applied to bind BMP molecules
[4]. This matrix engineering approach has enhanced bone
formation, but specific effects of released growth factors
could not be shown [30].
An alternative way of coupling growth factors to
inorganic carrier surfaces is a chemisorptive process using
linker molecules. With one end, the linker molecules bind
to the surface of the carrier and with the other end to the
growth factor. The chemical nature of the carrier surface
and the molecular structure of the growth factor to be
attached frequently determine the choice of the linker
molecules. Thiol anchors have been employed for this
purpose that bind to cysteine residues of organic molecules
using maleimide chemistry [29]. Phosphonate anchors are
commonly used to couple BMP2 to a carrier surface because
the seven cysteine residues are engaged in disulfide bonds
within the molecule and in the intermolecular disulfide bond
of the dimeric protein [1]. Phosphonate anchors bind to the
oxide groups of the material surface through their phospho-
nate groups. Modification of these anchor molecules using
N-hydroxysuccinimide/N-ethylcarbodiimide (NHS/EDC) or
N,N-carbonyldiimidazol chemistry on the free end of the
anchor molecule allows for covalent binding of the primary
amino groups of growth factor molecules. Chemisorptive
coupling of BMP has been reported to retard release from the
surface and enhance bone formation in a significant manner
[1, 33].
Valve metals like titanium can be also coated using
nanomechanical anchorage of organic molecules. This
strategy is based on the growth of oxide layers on the
titanium surface under anodic polarization. Molecules or
nanoparticles that are preliminary adsorbed on the initial
surface can be incorporated into the growing oxide layer.
Nanomechanical fixation has already been used for the
partial incorporation of a cyclic RGD-peptide conjugated to
phosphonate anchors [3] and fixation of adsorptively
immobilized fibrillar collagen [29]. Additional binding of
selected proteins such as RGD motifs can be accomplished
using thiol anchors [30].
Nanomechanical fixation as well as chemisorptive
binding of biologically active molecules to a biomaterial
surface, however, has the disadvantage that the sterilization
procedures which all implants have to undergo prior to
insertion could easily render the coated implant surface
inactive. Therefore, the concept of nanomechanical anchor-
age has been recently expanded to the regioselective
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incorporation of terminally functionalized oligonucleotides.
As the structure of oligonucleotides are much more likely to
survive sterilization procedures, they could act as anchor
strands for bioactive molecules by using hybridization with
complementary strands conjugated with biologically active
molecules after sterilization [21]. Different oligonucleotide
sequences would then allow for anchorage of more than
one growth factor molecule, and different strand lengths
can provide variable release kinetics. Nevertheless, this
concept requires further in vitro evaluation and assessment
of preclinical proof of principle.
Organic carriers
Like inorganic carriers, organic carriers can be divided into
those that originate from natural precursors and those that
are produced from purely synthetic polymers. Because
organic carriers allow for engineering of material compo-
sition and surface properties in conjunction with proteins to
a higher extent than inorganic carriers, they are likely to
have a higher potential to provide controlled release
characteristics.
Among the carriers of natural origin, collagen has
undergone the widest application as carrier for many
different biologically active molecules. Its potential as a
carrier for bone growth factors has been thoroughly
evaluated [2, 9, 40, 41]. Although it is the only carrier that
has received Food and Drug Administration (FDA) approval
for BMPs so far, native collagen sponges have only inferior
characteristics for retarded growth factor delivery [39].
Therefore, chemical modifications of the collagen fibers
have been performed to enhance the binding of the growth
factors and slow down the release. These modifications have
made use of the fact that collagen contains multiple heparin
binding sites on the one hand and that heparin also acts as
binding molecule for many growth factors. Coupling of
heparin to the collagen fibrils can allow for stronger binding
of growth factors and result in a slower release from the
collagen carrier. This approach has been successfully
performed for binding and release of vascular endothelial
growth factor [35, 43]. Alternative routes for coupling of
growth factors have been pursued using chemical modifica-
tions of the growth factor itself. Binding and release of
human recombinant bone morphogenic protein 2 (rhBMP2)
to collagen scaffolds have been improved by adding a
collagen binding domain to the N-terminal of the growth
factor molecule. In this way, bone formation could be
significantly increased in critical size defects compared to
controls [5].
Another organic carrier of natural origin is silk, a fibrous
protein, which is composed of fibroin and sericin proteins.
Silkworm silk in its original composition has shown to be
strongly immunogenic. Removal of the glue-like sericin
proteins, which act as binding agents for the native silk
fibroin threads, has rendered this material highly biocom-
patible [34]. The fibroin protein is a degradable protein that
can be regenerated as gels, films, or fibers for various
applications [22]. Coupling of biologically active molecules
such as RGD peptides, parathormone, and BMP2 to silk
fibers has been performed using NHS/EDC chemistry [22].
This type of coupling had resulted in retention of higher
amounts of growth factors on the biomaterial surface as
well as increased mineralization in vitro [16]. In vivo
testing of silk as carrier for BMP2 has also been
successfully demonstrated; however, in these applications,
the growth factor had been only adsorbed to the carrier
surface without using specific means of coupling [17, 19].
A third carrier of natural origin is chitosan, a degradable
polyaminosaccharide which is derived from the chitin shell
of shrimps. High molecular mass chitosan is fabricated as
fibrous textile structure by electrospinning. Growth factor
molecules can be coupled to chitosan using maleimide
chemistry [26]. This chemical conjugation has been shown
to be associated with significantly retarded release of BMP
from the surface of chitosan fibers as well as significantly
increased accumulation of calcium in MC3T3 cell cultures
when compared to carriers with adsorptive coating only
[24]. Preclinical testing of this carrier in conjunction with
BMP2 has shown significantly enhanced bone formation
using adsorbed and not chemically conjugated growth
factor molecules [7]. However, this carrier had failed to
produce sufficient bone tissue when being tested in a
clinical setting later on [6].
The majority of organic carriers of pure synthetic origin
are polymers of poly-α-hydroxy acids with polylactic acid
(PLA) and polyglycolic acid (PGA), and their derivatives
being the most common ones. These polymers degrade
through hydrolysis. Their degradation time can vary
considerably depending on composition, molecular weight,
and crystallinity.
Synthetic polymers derived from poly-α-hydroxy acids
have been tested extensively as carriers for bioactive
substances. Both PLA and PGA as well as combinations of
both have been used as delivery vehicles for bone growth
factors. Incorporation of growth factors into the polymer
matrix requires additional technology as the glass transition
temperature (the temperature at which the polymer becomes
liquid) of both PLA and PGA is well above the temperature
at which proteins denaturate. One intensely researched way
of integrating growth factors into the polymer matrix is the
application solvent technology. During this procedure, the
polymer is liquefied using organic solvents such as dichloro-
methane or methylene chloride after which the growth factor
is added. During evaporation of the solvent, the polymer
becomes solid and can release the incorporated growth factor
during degradation [42]. Porous carriers can be derived by
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combining solvent casting with particle leaching methods,
during which sodium chloride particles are added and
removed from the solid polymer afterwards by salt
leaching. More recent approaches have used amino termi-
nated poly(L-lactic-co-glycolic acid) and combined this
technology with NHS activated heparin which in turn
allows for targeted growth factor binding [12]. When
combined with BMP2, this amino-terminated heparin-
conjugated polymer has resulted in growth factor release
for more than 14 days in vitro and has significantly
enhanced bone formation compared to conventionally
prepared polymer carriers. However, concerns have been
raised in conjunction with this technique that residues of
organic solvents remain after evaporation which could
cause toxic reactions and lead to tissue irritation in vivo.
An alternative way of incorporating growth factors into
the polymer matrix that could avoid the use of organic
solvents is gas foaming. Gas foaming is performed using
high-pressure carbon dioxide and is particularly suitable for
amorphous poly-DL-lactic acid. Under high-pressure con-
ditions (approximately 100 bar), the carbon dioxide
molecules diffuse into the polymer between the PLA chains
and lead to reduction of the glass transition temperature so
that the polymer becomes liquid at body temperature. If a
lyophilized mixture of polymer granules and growth factor
is submitted to gas foaming in a mold, the polymer can
incorporate the growth factor that had been adsorbed and
lyophilized on the surface of the polymer granules [23, 38].
During decompression, the liquid polymer transforms into a
solid foam that fills the mold. The incorporation of growth
factors using this technology has shown to be superior to
adding growth factor to the solid porous matrix after gas
foaming of the polymer alone [25]. Implants produced with
this technology have been successfully tested as slow
release devices for BMP2 in vitro and preclinically [10,
31, 32].
One major drawback of the use of poly-α-hydroxy
polymers is the fact that their degradation is associated with
a periimplant drop in pH, which can cause tissue irritation
and produce detrimental effects on bone formation. More-
over, during degradation, thorough initial hydrolysis frag-
mentation of the polymer occurs, which elicits cellular
uptake and degradation. This cellular degradation process
can cause features of sterile inflammation with resorption of
adjacent bone tissue. Addition of neutralizing components
such as calcium carbonates and/or calcium phosphates can
help to reduce the acidic degradation products occurring
during resorption of the carrier [8, 27].
Another synthetic polymer which is currently being
researched intensely is polyethylene-glycol (PEG). PEG
molecules form a three-dimensional network in which
water can be absorbed to a multiple of its dry weight
forming a hydrogel. In this way, PEG offers the opportunity
to retain active factors in the matrix and to release them in a
controlled manner. Proteins and peptides can be bound into
the network via cystein groups and are released during
degradation of the network. Degradation occurs through
hydrolysis. Mechanical strength, degradation character-
istics, and, thereby, release kinetics of growth factors are
strongly depending on the molecular weigth of the PEG
carrier.
PEG has been used in conjunction with parathormon and
with BMP2 [13, 15]. As it has little mechanical stability, it
has been combined with calcium phosphate carriers [14] or
polymers that provide greater stability such as PLA [37].
All combinations had been successful in inducing new bone
formation; however, detailed release characteristics with
respect to molecular weight of the PEG polymer and
corresponding data that support a controlled release
function have not been reported yet.
Conclusions
Today, a large variety of scaffold materials exist that can
be used as carriers for bone growth factors. Loading of
these carriers through simple adsorption produces a burst
release of biological activity that is considered inappro-
priate from a physiological point of view. Therefore, a
critical feature for the suitability of these materials is the
ability to provide controlled release of the growth factor
molecules. An important precondition for this quality is a
defined coupling method that is used to bind the growth
factor to the carrier.
Inorganic carriers, which are currently widely used as
bone replacement materials and dental implants, are merely
loaded with growth factors by binding them to the material
surface. This can be accomplished by chemisorption using
linker molecules of various chemistry or, if valve metals
like titanium are involved, by nanomechanical anchorage of
anchor strands that then can bind growth factors. Preclinical
evidence for the efficacy of the majority of these
approaches exists; however, in clinical settings, only simple
adsorption of the growth factor to the carrier through soak
loading has been applied yet.
Organic carriers provide a higher variability with
respect to degradation characteristics, chemical modifica-
tion, and, thus, binding of growth factors. A number of
promising approaches exist that use polymers of both
natural and synthetic origin, which have been modified to
accommodate or bind bone growth factors for a controlled
or at least retarded release. Many of these materials have
undergone successful preclinical testing in various models.
Clinical approval of these concepts remains to be shown.
Currently, the only organic carrier in clinical use is
collagen.
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